Literature DB >> 22515978

Th17-related cytokines in inflammatory bowel diseases: friends or foes?

I Monteleone1, M Sarra, F Pallone, G Monteleone.   

Abstract

T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn's disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22515978     DOI: 10.2174/156652412800620066

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  37 in total

1.  Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients.

Authors:  Jin-Shan Feng; Zheng Yang; Yu-Zhen Zhu; Zhou Liu; Can-Can Guo; Xue-Bao Zheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

3.  Elevated proinflammatory cytokine IL-17A in the adjacent tissues along the adenoma-carcinoma sequence.

Authors:  Guanglin Cui; Hang Yang; Jianbo Zhao; Aping Yuan; Jon Florholmen
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

4.  Prevention of preterm birth by progestational agents: what are the molecular mechanisms?

Authors:  Christopher Nold; Monique Maubert; Lauren Anton; Steven Yellon; Michal A Elovitz
Journal:  Am J Obstet Gynecol       Date:  2013-03       Impact factor: 8.661

5.  Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis.

Authors:  Luigi Franchi; Ivan Monteleone; Ling-Yang Hao; Mark A Spahr; Wenpu Zhao; Xikui Liu; Kellie Demock; Aditi Kulkarni; Chuck A Lesch; Brian Sanchez; Laura Carter; Irene Marafini; Xiao Hu; Oksana Mashadova; Min Yuan; John M Asara; Harinder Singh; Costas A Lyssiotis; Giovanni Monteleone; Anthony W Opipari; Gary D Glick
Journal:  J Immunol       Date:  2017-02-27       Impact factor: 5.422

Review 6.  Current and emerging therapeutic targets for IBD.

Authors:  Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-01       Impact factor: 46.802

7.  Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease.

Authors:  M Friedrich; J Diegelmann; J Schauber; C J Auernhammer; S Brand
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

8.  IL-22 secreted by decidual stromal cells and NK cells promotes the survival of human trophoblasts.

Authors:  Ying Wang; Bing Xu; Ming-Qing Li; Da-Jin Li; Li-Ping Jin
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

Review 9.  Inflammatory bowel disease.

Authors:  Daniele Corridoni; Kristen O Arseneau; Fabio Cominelli
Journal:  Immunol Lett       Date:  2014-06-02       Impact factor: 3.685

10.  Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome.

Authors:  M Ostadkarampour; A Eklund; D Moller; P Glader; C Olgart Höglund; A Lindén; J Grunewald; J Wahlström
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.